<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Ergot Alkaloids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i981.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i981.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i981.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1017.htm" title="Previous: Eptifibatide">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i918.htm" title="Next: Ergometrine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i981">Ergot Alkaloids</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Ergot Alkaloids</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  ergot alkaloids possibly increased by atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1214.htm" name="_1214">Boceprevir</a></td><td class="cBV"><b>avoidance of  ergot alkaloids advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i874.htm" name="_874">Efavirenz</a></td><td class="cBV"><b>increased risk of ergotism when  ergot alkaloids given with efavirenz—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  ergot alkaloids advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b>plasma concentration of  ergot alkaloids possibly increased by ticagrelor </b></td><td></td></tr></tbody></table><p><b>Ergometrine</b> belongs to
      <b>Ergot Alkaloids</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1100.htm">Halothane</a></td><td>effects of  ergometrine on the parturient uterus reduced by halothane </td><td></td></tr></tbody></table><p><b>Ergotamine and Methysergide</b> belongs to
      <b>Ergot Alkaloids</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





















<tr><td><a href="41001i925.htm">Almotriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with almotriptan (avoid ergotamine and methysergide for 6 hours after almotriptan, avoid almotriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with imidazoles—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with triazoles—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>increased peripheral vasoconstriction when  ergotamine and methysergide given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with cimetidine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with eletriptan (avoid ergotamine and methysergide for 24 hours after eletriptan, avoid eletriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i965.htm">Frovatriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with frovatriptan (avoid ergotamine and methysergide for 24 hours after frovatriptan, avoid frovatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with macrolides—avoid concomitant use</b></td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i573.htm">Naratriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with naratriptan (avoid ergotamine and methysergide for 24 hours after naratriptan, avoid naratriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td>possible risk of hypertension when  ergotamine and methysergide given with reboxetine </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i862.htm">Rizatriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with rizatriptan (avoid ergotamine and methysergide for 6 hours after rizatriptan, avoid rizatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with sumatriptan (avoid ergotamine and methysergide for 6 hours after sumatriptan, avoid sumatriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr><tr><td><a href="41001i690.htm">Sympathomimetics</a></td><td>increased risk of ergotism when  ergotamine and methysergide given with sympathomimetics </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>increased risk of ergotism when  ergotamine and methysergide given with telithromycin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i209.htm">Tetracyclines</a></td><td>increased risk of ergotism when  ergotamine and methysergide given with tetracyclines </td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td class="cBV"><b>increased risk of vasospasm when  ergotamine and methysergide given with zolmitriptan (avoid ergotamine and methysergide for 6 hours after zolmitriptan, avoid zolmitriptan for 24 hours after ergotamine and methysergide)</b></td><td></td></tr></tbody></table><p><b>Methysergide</b> belongs to
      <b>Ergot Alkaloids</b>
          but has no specific interaction information.
        </p><div>Methysergide interactions as for ergotamine and methysergide</div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i918.htm" title="Ergometrine">Ergometrine</a></li><li id="_41001i563"><a href="41001i563.htm" title="Ergotamine and Methysergide">Ergotamine and Methysergide</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1017.htm">Previous: Eptifibatide</a> | <a class="top" href="41001i981.htm#">Top</a> | <a accesskey="]" href="41001i918.htm">Next: Ergometrine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>